Study on value of fluticasone propionate combined with montelukast in the treatment of children with bronchial asthma and allergic rhinitis
Objective To explore the clinical effect of fluticasone propionate combined with montelukast in the treatment of children with bronchial asthma and allergic rhinitis.Methods A total of 60 children with bronchial asthma and allergic rhinitis were selected and divided into the control group and the observation group by random number table,each with 30 cases.The control group was treated with fluticasone propionate,and the observation group was treated with fluticasone propionate and montelukast.Both groups were compared in terms of clinical effect,lung function indicators(forced vital capacity,peak expiratory flow rate,forced expiratory volume in one second),scores of asthma symptoms and rhinitis symptoms,levels of inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],and occurrence of adverse reactions.Results(i)The total effective rate of the observation group was 96.67%,which was higher than 73.33%of the control group(P<0.05).(ii)After treatment,the forced vital capacity,peak expiratory flow rate and forced expiratory volume in one second were increased in both groups;the forced vital capacity in the observation group was(3.99±1.03)L,the peak expiratory flow rate was(172.32±27.53)L/min and the forced expiratory volume in one second was(2.64±0.62)L,which were higher than(3.36±0.97)L,(154.37±27.42)L/min and(1.97±0.56)L in the control group;the difference was significant(P<0.05).(iii)After treatment,the scores of asthma symptoms and rhinitis symptoms in both groups were decreased;and the scores of asthma symptoms and rhinitis symptoms in the observation group were(4.93±1.96)and(3.52±1.27)points,which were lower than(6.60±2.22)and(4.21±1.38)points in the control group;the difference was significant(P<0.05).(iv)After treatment,the levels of IL-6 and TNF-α were decreased in both groups;and the observation group had IL-6 of(93.80±23.63)ng/L and TNF-α of(313.51±37.16)ng/L,which were lower than(109.49±26.38)and(351.40±46.38)ng/L in the control group;the difference was significant(P<0.05).(v)There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The clinical effect of fluticasone propionate combined with montelukast in the treatment of children with bronchial asthma and allergic rhinitis is prominent.It can not only effectively improve the symptoms of asthma and rhinitis in children,but also improve the lung function and inflammatory factor level in children.It is recommended to be widely used in clinical treatment.
Fluticasone propionateMontelukastBronchial asthma in childrenAllergic rhinitis
万方数据
维普
